Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. [electronic resource]
Producer: 20040122Description: 818-26 p. digitalISSN:- 0168-8278
- Adolescent
- Adult
- Aged
- Alanine Transaminase -- blood
- Antiviral Agents -- administration & dosage
- Drug Administration Schedule
- Drug Resistance, Microbial
- Drug Therapy, Combination
- Female
- Genetic Variation
- Hepatitis B e Antigens -- analysis
- Hepatitis B virus -- drug effects
- Hepatitis B, Chronic -- drug therapy
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Lamivudine -- administration & dosage
- Male
- Middle Aged
- Recombinant Proteins
- Reverse Transcriptase Inhibitors -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.